Analyzing Collegium Pharmaceutical (NASDAQ:COLL) and Pivotal Therapeutics (OTCMKTS:PVTTF)

Pivotal Therapeutics (OTCMKTS:PVTTF) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of current recommendations for Pivotal Therapeutics and Collegium Pharmaceutical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pivotal Therapeutics	0	0	0	0	0.00
Collegium Pharmaceutical	0	2	5	0	2.71

Collegium Pharmaceutical has a consensus target price of $52.80, indicating a potential upside of 16.04%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Pivotal Therapeutics.

Risk and Volatility

Pivotal Therapeutics has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Earnings and Valuation

This table compares Pivotal Therapeutics and Collegium Pharmaceutical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pivotal Therapeutics	N/A	N/A	N/A	N/A	N/A
Collegium Pharmaceutical	$631.45 million	2.28	$69.19 million	$1.61	28.26

Collegium Pharmaceutical has higher revenue and earnings than Pivotal Therapeutics.

Profitability

This table compares Pivotal Therapeutics and Collegium Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pivotal Therapeutics	N/A	N/A	N/A
Collegium Pharmaceutical	7.72%	102.03%	15.24%

Summary

Collegium Pharmaceutical beats Pivotal Therapeutics on 8 of the 8 factors compared between the two stocks.

About Pivotal Therapeutics

Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.